Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
12/2003
12/04/2003US20030225108 Process for making substituted pyrazoles
12/04/2003US20030224990 IGF-binding protein-derived peptide or small molecule
12/04/2003US20030224487 Novel cytokine zcytor17 ligand
12/04/2003US20030224053 Mixture of a polymer, an active ingredient and a solvent capable of being preserved within a container such that on release forms a peelable, water removable, agent-releasing film on the surface of skin
12/04/2003US20030224045 Combination immediate release sustained release levodopa/carbidopa dosage forms
12/04/2003US20030223941 Methods for modulating phototoxicity
12/04/2003CA2486962A1 Compounds
12/03/2003EP1366045A2 Efficient process for the preparation of a factor xa inhibitor
12/03/2003EP1082304B1 NEW CRYSTALLINE POLYMORPHIC FORM OF 1-METHYL-5-p-TOLUOYLPYRROLE-2-ACETAMIDOACETIC ACID GUAIACYL ESTER (MED 15)
12/03/2003EP1075483B1 Hygromycin a derivatives
12/03/2003CN1460024A Use of FVIIa or tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
12/03/2003CN1129796C Medicine box for detecting hepatitis virus C and use thereof
12/03/2003CN1129602C 11-(substituted phenyl) estra-4,9-diene derivatives
12/02/2003US6656939 Pyrazole compounds useful as protein kinase inhibitors
12/02/2003US6656729 Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
12/02/2003US6656469 Treatment of nicotine dependence from tobacco products
12/02/2003CA2046904C Cd4 specific recombinant antibody
11/2003
11/29/2003WO2003096988A2 Tr4/tr2 response elements
11/29/2003CA2486351A1 Tr4/tr2 response elements
11/27/2003WO2003097636A1 Novel compounds and their use
11/27/2003WO2003096985A2 3d structure of the tsg101 uev domain
11/27/2003WO2003096980A2 Bicyclic modulators of androgen receptor function
11/27/2003WO2003096976A2 Microcrystalline cewllulose compositions
11/27/2003WO2003096973A2 A direct cellular energy delivery system
11/27/2003WO2003096969A2 Novel lambda phage display system and the process
11/27/2003WO2003096967A2 Dna vaccines encoding heat shock proteins
11/27/2003WO2003084463A3 Apparatus for moxa cautery
11/27/2003WO2003073981A3 Novel of cytokine inhibitors
11/27/2003WO2003065990A3 Stenoprophiluric generation and isolation of chemical products
11/27/2003WO2003053338A3 Novel chimeric rev, tat, and nef antigens
11/27/2003WO2002062302A3 Steroidal derivatives
11/27/2003US20030220496 3-(optionally hydroxyl)-4-(cyclopropylcarbonyl)-cumene intermediate
11/27/2003US20030220391 Taxoids such as 3'-tert-butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N -debenzoyl-4-O-methoxycarbonyl-paclitaxel, used as antitumor agents
11/27/2003US20030220388 Indoline derivatives
11/27/2003US20030220362 Novel inhibitors of formation of advanced glycation endproducts (AGEs)
11/27/2003US20030220358 A1 adenosine receptro antagonists
11/27/2003US20030220353 Useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3
11/27/2003US20030220303 GABAB Receptor Agonists; used to treat gastrointestinal disorders, especially GERD
11/27/2003US20030220282 Antisense modulation of PTP1B expression
11/27/2003US20030219723 Bioassys for identifying hepatitis C viricidal agents; drug screening
11/27/2003US20030219479 Including a mucoadhesive layer, containing a non-ionic polymer, a ionic polymer, a swelling modifier, a buffer; an effervescent layer containing a permeatin enhancer, an effervescent couple, and a binder; and an active agent
11/27/2003US20030219378 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/27/2003CA2485463A1 A direct cellular energy delivery system
11/27/2003CA2483619A1 Novel compounds and their use
11/26/2003EP1364056A2 Method for ultra-high resolution mapping of genes and determination of genetic networks among genes underlying phenotypic traits
11/26/2003EP1363899A1 Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
11/26/2003EP1363664A2 Synthetic vaccine agents
11/26/2003EP1363650A2 AQUATIC ANIMAL TREATMENT METHOD AND COMPOSITION CONTAINING i PIMENTA /i EXTRACT
11/26/2003EP1363647A1 A method to enhance the immune system and used for the prevention and treatment of infectious diseases
11/26/2003EP1363638A2 Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
11/26/2003EP1363627A2 Treatment of solid tumours with rapamycin derivatives
11/26/2003EP1091933B1 Substituted beta-diketones and their use
11/26/2003EP0814813B1 Use of penciclovir for the treatment of human herpes-virus-8
11/26/2003CN1128805C Polymorphic clopidogrel hydrogenesulphate form and its preparing method and pharmaceutical compositions
11/26/2003CN1128801C Triazolo (4,5-D) pyrimidine compounds
11/25/2003US6653519 Reactive nanoparticles as destructive adsorbents for biological and chemical contamination
11/25/2003US6653326 Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof
11/25/2003US6653301 For therapy of cancer, diabetes and Alzheimer's disease
11/25/2003US6653300 Pyrazole compounds useful as protein kinase inhibitors
11/22/2003WO2005032452A2 Alkyl-substituted pcdf as a treatment for prostate cancer
11/22/2003CA2497877A1 Alkyl pcdf as a treatment for prostate cancer
11/20/2003WO2003095559A1 Compositions comprising anionic functionalized polyorganosiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents to surfaces treated therewith
11/20/2003WO2003095470A1 Platinum complexes having antitumor activity
11/20/2003WO2003094943A1 Formulations useful in the treatment of male and female impotence
11/20/2003WO2003094892A1 Conversion of amorphous material to a corresponding crystalline material by spray drying and utilization of the crystalline spray dried material in drug formulations
11/20/2003WO2003094842A2 Conjugates comprising central nervous system active drug
11/20/2003WO2003084479A3 Large scale methods of producing adenovirus and adenovirus seed stocks
11/20/2003WO2003068145A3 Herbal immune system stimulant
11/20/2003WO2003041647A3 Synthesis and purification of valacyclovir
11/20/2003WO2003039459A3 Viral vector production methods and compositions
11/20/2003WO2003039458A3 TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α
11/20/2003WO2003011217A9 Grifola extracts and methods of use thereof
11/20/2003US20030216555 Processes for preparing clarithromycin polymorphs
11/20/2003US20030216458 Combination therapy for the treatment of migraine
11/20/2003US20030216445 Osteoporosis; immunosuppressants; wound healing agent
11/20/2003US20030216419 Isomeric fused pyrrolocarbazoles and isoindolones
11/20/2003US20030216392 Aryl or heteroaryl substituted ethylcarbonylsulfonamide derivatives used as inhibitors of neutrophils chemotaxis and degranulation induced by interleukin 8
11/20/2003US20030216348 Aminosugar, glycosaminoglycan, and S-Adenosylmethionine composition for the treatment and repair of connective tissue
11/20/2003US20030215916 Comprises nucleotide sequences coding membrane protein for diagnosisng and treating tumor, nervous sytem, reproductive, pain and sexual disorders
11/20/2003US20030215835 Designing oligonucleotides for diagnosing, monitoring, prognosticating, preventing or treating metabolic disorders; forensics; gene therapy; drug screening
11/20/2003US20030215542 Reduction of cystine containing polypeptides such as gliadins, glutenins, albumin or globulins, using thioredoxin or transferase enzymes; deactivation of neurotoxins
11/20/2003US20030215457 Comprising a nucleic acid, a polypeptide encoded by the nucleic acid, and a compound, preferably an antibody or fragment thereof, that binds to the polypeptide, preferably binding to the extracellular domain of LIV-1 polypeptide
11/20/2003US20030215445 Concerns an 88 kDa glycoprotein growth factor ("GP88" or "PCDGF") and compositions and methods which affect the expression and biological activity of GP88; useful for diagnosis and treatment of diseases
11/20/2003CA2485431A1 Platinum complexes having antitumor activity
11/20/2003CA2485264A1 Formulations useful in the treatment of male and female impotence
11/20/2003CA2484891A1 Conjugates comprising central nervous system active drug
11/19/2003EP1362033A1 Pyridine matrix metalloproteinase inhibitors
11/19/2003EP1214076B1 Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
11/19/2003EP0874631B1 Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
11/18/2003US6649633 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
11/18/2003US6649601 Bisphosphonic compound
11/13/2003WO2003092609A2 System and method of treating abnormal tissue in an organ having a layered tissue structure
11/13/2003WO2003092592A2 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
11/13/2003WO2003092582A2 Chimeric ebola virus envelopes and uses therefor
11/13/2003WO2003092542A2 Injectable chondrocyte implant
11/13/2003WO2003061553A3 An extract of acanthopanax koreanum for the treatment or prevention of hepatitis or the liver protective drug
11/13/2003WO2003051392A3 Streptococcus pneumoniae vaccine
11/13/2003WO2003045310A3 Digital assay
11/13/2003WO2002096879A9 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
11/13/2003US20030212145 Parkinson's disease; cognition activators; central nervous system disorders
1 ... 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 ... 295